Eltrombopag drug information sorting

1、 Drug name

1. Common name: Eltrombopag

2. Product Name: PROMASTA ®

2、 Indications

Used to treat thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have insufficient response to glucocorticoids, immunoglobulin, or splenectomy. Only applicable to patients with increased risk of bleeding due to thrombocytopenia and clinical conditions, and should not be used to attempt to normalize platelet counts.

3、 Specifications and characteristics

1. 25mg tablets: round.

2. 50mg tablets: round.

4、 Main components

Each tablet contains ezetimibe ethanolamine salt (equivalent to 25mg or 50mg of ezetimibe free acid).

5、 Usage and dosage

1. Initial dose:

Most patients: 50mg once daily;

East Asian or moderate/severe liver injury patients: 25mg once daily.

2. Medication time: Take on an empty stomach (1 hour before or 2 hours after meals), avoid taking with drugs/foods containing multivalent cations (such as iron, calcium, magnesium) (with a 4-hour interval).

3. Maximum dose: not exceeding 75mg/day.

6、 Dose adjustment

1. When the platelet count result is less than 50 × 10 ⁹/L (continuous for ≥ 2 weeks), the daily dose should be increased by 25mg (maximum 75mg/day)

2. When the platelet count result is 200-400 × 10 ⁹/L, the daily dose should be reduced by 25mg and evaluated after 2 weeks

3. When the platelet count result is greater than 400 × 10 ⁹/L, medication should be suspended. If the platelet count is less than 150 × 10 ⁹/L, the dosage should be reduced by 25mg and restarted

4. When the platelet count result is>400 × 10 ⁹/L (still occurring at the lowest dose), the medication should be permanently discontinued

7、 Medication precautions

1. Dietary taboos: Avoid taking with dairy products, antacids, or mineral supplements (with a 4-hour interval).

2. Missed/Vomiting: If missed, it should be taken immediately upon recollection (unless close to the next dose); No need to take additional medication after vomiting.

3. Monitoring requirements:

Regularly check liver function (ALT/AST, bilirubin) and blood routine (including platelet count and peripheral blood smear) before and during treatment.

After discontinuing the medication, platelets should be monitored for at least 4 weeks (possibly rebounding to lower levels).

8、 Medication for special populations

1. Patients with liver injury: The initial dose for moderate/severe cases is 25mg/day, and close monitoring of liver function is required.

2. Pregnant women: May cause fetal harm, need to weigh the pros and cons (pregnancy registration phone: 1-888-825-5249).

3. Breastfeeding period: Suspend breastfeeding or medication.

4. Children/Elderly: Safety is not clear, elderly people need to adjust dosage carefully.

9、 Adverse reactions

1. Common symptoms include nausea (6%), vomiting (4%), heavy menstrual flow (4%), muscle pain (3%), sensory abnormalities (3%), cataracts (3%), and elevated ALT/AST (2%).

2. Serious: Hepatotoxicity, bone marrow fibrosis, thrombosis/embolism, exacerbation of thrombocytopenia after discontinuation of medication.

10、 Contraindications

There are no clear contraindications, but it is necessary to avoid using it for non ITP induced thrombocytopenia (such as myelodysplastic syndrome).

11、 Drug interactions

1. OATP1B1 substrate (such as rosuvastatin): may increase exposure, requiring a 50% reduction and monitoring.

2. Multivalent cations (such as iron and calcium agents): significantly reduce absorption, requiring a 4-hour interval.

12、 Storage method

Not explicitly stated, it is recommended to refer to the labeling conditions of drug packaging (usually room temperature and light avoidance).

eltrombopaginformation